Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 6/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038087 | 1.00 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL4035789 | 1.00 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| Ammonia Solution, Strong SCHEMBL9243093 | 0.98 | L3MBTL1 (0.37) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL4202492 | 0.85 | L3MBTL1 (0.36) | L3MBTL1HTTALDH1A1DPP4DPP8 | |
| SCHEMBL12299850 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL12658782 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL12658780 | 0.83 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL23372707 | 0.79 | L3MBTL1 (0.38) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL21959058 | 0.79 | HTT (0.39) | L3MBTL1HTTALDH1A1KMT2A | |
| SCHEMBL31474253 | 0.79 | L3MBTL1 (0.41) | L3MBTL1HTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021022163-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-7709479-B1 | Quinazoline derivatives and their use as pharmaceuticals | ASTRAZENECA (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080058365-A1 | Fused heterocyclic compounds | AMGEN INC. | 2008-03-06 | — | — | US | disclosed |
| US-7253179-B2 | Fused heterocyclic compounds | AMGEN INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040147538-A1 | Fused heterocyclic compounds | AMGEN INC. | 2004-07-29 | — | — | US | disclosed |
| US-6515122-B1 | The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. | LION BIOSCIENCE AG (DE) | 2003-02-04 | — | — | US | disclosed |
| EP-0604895-A1 | Pigment compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-07-06 | — | — | EP | disclosed |
| US-5317015-A | Azacyclic bisphosphonates as anticholesterolemic agents | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-05-31 | — | — | US | disclosed |
| EP-0273401-B1 | ISOINDOLIN-1-ONE DERIVATIVE AND ANTIARRHYTHMIC AGENT | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1992-11-11 | — | — | EP | disclosed |
| US-4849441-A | Isoindolin-1-one derivative and antiarrhythmic agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-07-18 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0000977-B1 | AGGREGATED POLYELECTROLYTES, THEIR PREPARATION AND USES IN THE FRACTIONATION OF BLOOD AND OTHER PROTEINACEOUS SUBSTANCES | MONSANTO COMPANY (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4118554-A | HEATING IN INERT ORGANIC SOLVENT, CONTAINS AMINE-IMIDE FUNCTIONAL GROUPS | MONSANTO COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4097473-A | ADSORPTION ON ETHYLENE-MALEIC ANHYDRIDE COPOLYMER CONTAINING PENDANT DIMETHYLAMINOPROPYL FUNCTIONAL GROUPS | MONSANTO COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-3959477-A | Methods of protection against emesis in mammals by administration of a heterocyclic benzamide | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | L3MBTL1 4026/4885HTT 1814/4885ALDH1A1 4332/4885 |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | L3MBTL1 4026/4885HTT 1814/4885ALDH1A1 4332/4885 |
| US-20080058365-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | L3MBTL1 3838/4885HTT 396/4885ALDH1A1 1509/4885 |
| US-20040147538-A1 | Fused heterocyclic compounds | GIPR, MC4R, GPR119 | L3MBTL1 3838/4885HTT 396/4885ALDH1A1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.